H G Derigs
Overview
Explore the profile of H G Derigs including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
260
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schlenk R, Weber D, Herr W, Wulf G, Salih H, Derigs H, et al.
Leukemia
. 2019 Feb;
33(8):1923-1933.
PMID: 30728457
The aim of this randomized phase-II study was to evaluate the effect of substituting cytarabine by azacitidine in intensive induction therapy of patients with acute myeloid leukemia (AML). Patients were...
2.
Nagel G, Weber D, Fromm E, Erhardt S, Lubbert M, Fiedler W, et al.
Ann Hematol
. 2017 Nov;
96(12):1993-2003.
PMID: 29090343
We describe genetic and clinical characteristics of acute myeloid leukemia (AML) patients according to age from an academic population-based registry. Adult patients with newly diagnosed AML at 63 centers in...
3.
Derigs H, Morgan D, Hoffman R, Litz S, Srour E, Brandt J, et al.
Platelets
. 2010 Nov;
6(1):24-30.
PMID: 21043585
Terminal megakaryocytic development is characterized by nuclear poly ploidization, appearance of specific granules, and enhanced expression of membrane platelet glycoproteins. We utilized a human GM-CSF-dependent cell line, MB-02, which is...
4.
Schmoll H, Souchon R, Krege S, Albers P, Beyer J, Kollmannsberger C, et al.
Ann Oncol
. 2004 Aug;
15(9):1377-99.
PMID: 15319245
Germ cell tumour is the most frequent malignant tumour type in young men with a 100% rise in the incidence every 20 years. Despite this, the high sensitivity of germ...
5.
Lehmann J, Retz M, Steiner G, Albers P, Jaeger E, Knuth A, et al.
Urologe A
. 2003 Sep;
42(8):1074-86.
PMID: 14513232
Of 405 patients with stage IV transitional cell carcinoma from an international multicenter phase III trial, 70 were randomized in Germany to receive either gemcitabine/cisplatin or standard MVAC systemic chemotherapy...
6.
Hess G, Flohr T, Derigs H
Ann Hematol
. 2003 Mar;
81 Suppl 2:S54-5.
PMID: 12611079
In vivo purging may avoid relapse after high dose therapy (HDT) for relapsed lymphoma. Therefore, we have evaluated feasibility and efficacy of Rituximab as in vivo purging agent included into...
7.
Derigs H
Cytotherapy
. 2002 Jun;
2(6):445-53.
PMID: 12044225
Background: Autologous stem-cell transplantation has proved curative therapy for relapsed NHL. However, recurrence of underlying disease remains the major cause of treatment failure in this setting. Methods: Development of effective...
8.
Flohr T, Hess G, Kolbe K, Gamm H, Nolte H, Stanislawski T, et al.
Bone Marrow Transplant
. 2002 Jun;
29(9):769-75.
PMID: 12040475
The purpose of this study was to evaluate feasibility and efficacy of Rituximab included into a sequential salvage protocol for CD20(+) B-NHL in relapse or induction failure. Twenty-seven patients with...
9.
Foncuberta M, Cagnoni P, Brandts C, Mandanas R, Fields K, Derigs H, et al.
J Immunother
. 2001 Sep;
24(4):384-8.
PMID: 11565840
Transforming growth factor (TGF)-beta3 has been hypothesized to prevent or alleviate oral mucositis (OM) in cancer patients receiving high-dose chemotherapy (CT). Two double-blind, placebo-controlled, multicenter, phase II studies of TGF-beta3...
10.
Kreiter S, Winkelmann N, Schneider P, Schuler M, Fischer T, Ullmann A, et al.
Bone Marrow Transplant
. 2001 Aug;
28(2):157-61.
PMID: 11509933
We investigated whether a T cell-reduced allogeneic stem cell transplant (SCT) with minimal conditioning and subsequent donor lymphocyte infusions (DLI) could reduce the incidence and severity of GVHD while retaining...